-
公开(公告)号：US20250154288A1
公开(公告)日：2025-05-15
申请号：US18800888
申请日：2024-08-12
Inventor： Jae U. Jeong , Valer Jeso , Beth Anne Knapp-Reed , Andrew Peter Marcus , James P. Phelan , Matthew Robert Sender , Brandon James Turunen
Abstract: The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.
-
Patent Agency Ranking
公开(公告)号：US20250064947A1
公开(公告)日：2025-02-27
申请号：US18812114
申请日：2024-08-22
Inventor： Christina Ng Di Marco , Matthew Robert Sender , Brandon James Turunen
IPC: A61K47/55 , A61K39/395 , A61K47/60
Abstract: The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer.
-
公开(公告)号：US20250057958A1
公开(公告)日：2025-02-20
申请号：US18802386
申请日：2024-08-13
Inventor： Peiling Chen , Michael Gerard Darcy , Jason W. Dodson , Beth Anne Knapp-Reed , Joseph Paul Marino, JR. , Jeffrey Alan Oplinger , Matthew Robert Sender , Brandon James Turunen , Guosen Ye , Cunyu Zhang
IPC: A61K47/54
Abstract: The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.
-
公开(公告)号：US20250049932A1
公开(公告)日：2025-02-13
申请号：US18808367
申请日：2024-08-19
Inventor： Christina Ng Di Marco , Matthew Robert Sender , Brandon James Turunen
IPC: A61K47/55 , A61K39/395 , A61K47/60
Abstract: The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, or autoimmune diseases.
-
公开(公告)号：US20250057827A1
公开(公告)日：2025-02-20
申请号：US18808401
申请日：2024-08-19
Inventor： Christina Ng Di Marco , Matthew Robert Sender , Brandon James Turunen
IPC: A61K31/4439 , C07D401/04 , C07K16/16
Abstract: The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer.
-
公开(公告)号：US20250051479A1
公开(公告)日：2025-02-13
申请号：US18802915
申请日：2024-08-13
Inventor： Brandon James Turunen , Cunyu Zhang
Abstract: The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, or autoimmune diseases.
-
-
-
-
-
Search Results
6
records
(took 0.017 seconds)
